TY - JOUR
T1 - Comparative Study of Low-dose Pioglitazone or Metformin Treatment in Ia pa nese Diabetic Patients with Metabolic Syndrome
AU - Kato, T.
AU - Sawai, Y.
AU - Kanayama, H.
AU - Taguchi, H.
AU - Terabavashi, T.
AU - Taki, F.
AU - Yamada, K.
AU - Yamazaki, Y.
AU - Hayakawa, N.
AU - Suzuki, A.
AU - Oda, N.
AU - Katada, N.
AU - Itoh, M.
PY - 2009/11
Y1 - 2009/11
N2 - The aim of this study was to determine whether a relatively low dose of pioglitazone or metformin was effective in diabetic patients with metabolic syndrome. Fifty diabetic patients with metabolic syndrome were randomly assigned to a low-dose pioglitazone (15mg/day) treatment group or a low-dose metformin (500mg/day) treatment group. Drugs were administered for 12 weeks. Systolic and diastolic blood pressure, heart rate, body mass index, triglyceride (TC), HDL and LDLcholesterol, fasting plasma glucose (FPG), fasting plasma insulin (IRI), postprandial glucose, and HOMA-IR in the 75gOGTT, HbA1c, high-sensitivity CRP (hs-CRP) determined by cervical artery echography, and pulse wave velocity (PWV) were measured before/after 12-week drug administra-tion. Significant decreases in HbA1c and HOMAIR were noted in the pioglitazone group, along with significant decreases in TG, AST, ALT, blood pressure, hs-CRP and PWV. Significant decreases in HbAIc, HOMA-IR, BMI and waist circumference were noted in the metformin group. The pioglitazone group significantly improved the values for ALT, systolic blood pressure, hs-CRP and PWV compared to the metformin group. However, the metformin group demonstrated significant improvement in BMI compared with the pioglitazone group. Using a low dose regimen, pioglitazone significantly improved blood pressure and hepatic function and may be more effective than metformin to reduce risk factors in Japanese diabetic patients with metabolic syndrome at preventing atherosclerosis.
AB - The aim of this study was to determine whether a relatively low dose of pioglitazone or metformin was effective in diabetic patients with metabolic syndrome. Fifty diabetic patients with metabolic syndrome were randomly assigned to a low-dose pioglitazone (15mg/day) treatment group or a low-dose metformin (500mg/day) treatment group. Drugs were administered for 12 weeks. Systolic and diastolic blood pressure, heart rate, body mass index, triglyceride (TC), HDL and LDLcholesterol, fasting plasma glucose (FPG), fasting plasma insulin (IRI), postprandial glucose, and HOMA-IR in the 75gOGTT, HbA1c, high-sensitivity CRP (hs-CRP) determined by cervical artery echography, and pulse wave velocity (PWV) were measured before/after 12-week drug administra-tion. Significant decreases in HbA1c and HOMAIR were noted in the pioglitazone group, along with significant decreases in TG, AST, ALT, blood pressure, hs-CRP and PWV. Significant decreases in HbAIc, HOMA-IR, BMI and waist circumference were noted in the metformin group. The pioglitazone group significantly improved the values for ALT, systolic blood pressure, hs-CRP and PWV compared to the metformin group. However, the metformin group demonstrated significant improvement in BMI compared with the pioglitazone group. Using a low dose regimen, pioglitazone significantly improved blood pressure and hepatic function and may be more effective than metformin to reduce risk factors in Japanese diabetic patients with metabolic syndrome at preventing atherosclerosis.
UR - http://www.scopus.com/inward/record.url?scp=70450265353&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=70450265353&partnerID=8YFLogxK
U2 - 10.1055/s-0029-1202792
DO - 10.1055/s-0029-1202792
M3 - Article
C2 - 19924605
AN - SCOPUS:70450265353
SN - 0947-7349
VL - 117
SP - 593
EP - 599
JO - Experimental and Clinical Endocrinology and Diabetes
JF - Experimental and Clinical Endocrinology and Diabetes
IS - 10
ER -
